Caplin Point Laboratories has announced strong financial results for the fiscal year ended March 31, 2026, reporting a total revenue of ₹2,303 crore and a 20.1% YoY increase in Profit After Tax (PAT) to ₹650 crore. The Board of Directors has declared an interim dividend of ₹4.00 per share (200%). The company continues to maintain a strong balance sheet, remaining debt-free with significant free cash reserves of ₹1,471 crore.
Strong Financial Growth
For the fiscal year 2026, the company recorded a total revenue of ₹2,303 crore, representing a 13.2% year-on-year growth. Net Profit After Tax (PAT) reached ₹650 crore, driven by steady growth across emerging markets and regulated markets, particularly the United States. The company’s basic Earnings Per Share (EPS) improved significantly to ₹84.36 for the year.
Dividend and Strategic Outlook
Reflecting its strong cash flow position, the Board of Directors has declared an interim dividend of ₹4.00 per equity share (representing 200% on a face value of ₹2), with May 30, 2026, fixed as the record date. The company remains committed to its strategy of sustainable expansion, supported by an enhanced Capex budget of over ₹1,000 crore, aimed at augmenting production capacities and deepening backward integration.
Key Operational Highlights
- US and Regulated Markets: The US business recorded ₹471 crore in revenue, marking 28.7% growth. Caplin Steriles continues to see excellent traction, with an ANDA tally reaching 59 approvals.
- Emerging Markets: Latin America remains a robust growth engine, with the company entering the CNS segment and launching branded pre-filled syringes.
- Future Readiness: The company is expanding its infrastructure, with multiple new facilities (such as the Oncology API unit and COL Injectable facility) progressing towards completion in FY27 and FY28.
Robust Balance Sheet
Caplin Point maintains a fortress balance sheet, closing the year with ₹1,471 crore in free cash reserves and ₹2,726 crore in total liquid assets. The company remains debt-free, positioning it well to finance its ongoing capital expenditure through internal accruals while maintaining financial discipline.
Source: BSE
